Parabolan 100mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Usage

1. Research the compound's pharmacological history and your jurisdiction's regulations before beginning — Parabolan's original clinical dosing provides a useful baseline reference for conservative starting points.
2. Inspect each Balkan Pharmaceuticals ampoule for clarity, particle-free solution, and an intact seal before use; discard any ampoule with visible particulate matter.
3. Break the ampoule at the scored neck using a sterile gauze wrap — the single-dose format means the entire 1 ml contents must be drawn and administered in one session.
4. Draw the oil solution using an 18–21 gauge drawing needle, then switch to an appropriate intramuscular injection needle (23–25 gauge, 1–1.5 inch) for administration into a large muscle group (glute, vastus lateralis).
5. Follow an injection schedule consistent with the ester's extended-release characteristics — spacing injections evenly across the week maintains steadier plasma androgen levels than infrequent single large doses.
6. Log each ampoule's batch number and injection date; Balkan Pharmaceuticals' traceable batch certificates allow you to cross-reference your HPLC-verified lot against your cycle records for full accountability.

Warnings

Frequently asked questions

Where did Trenbolone Hexahydrobenzylcarbonate originally come from?

Trenbolone Hexahydrobenzylcarbonate was originally developed by Roussel-UCLAF, a French pharmaceutical company, during the late 1960s. It was commercialised under the brand name Parabolan by the French firm Negma beginning in 1980, with a licensed clinical indication for conditions including androgen deficiency and muscle-wasting disorders. It remains the only trenbolone ester ever approved for human pharmaceutical use.

When was the original Parabolan discontinued and why?

Negma discontinued the original Parabolan in 1997. The discontinuation was a commercial decision rather than a response to safety findings — the product was not withdrawn due to adverse event data or regulatory action. This left a significant gap in the availability of pharmaceutical-grade Trenbolone Hexahydrobenzylcarbonate, which specialist manufacturers like Balkan Pharmaceuticals subsequently addressed through GMP-compliant production.

How has the use of Trenbolone Hexahydrobenzylcarbonate evolved since its 1980 approval?

Initially prescribed for hypogonadism and cachexia in France, the compound shifted predominantly into performance and physique contexts following Negma's 1997 market withdrawal. Post-discontinuation, the hexahydrobenzylcarbonate ester became the subject of considerable interest in strength sports owing to its extended-release characteristics relative to shorter trenbolone esters. Modern manufacturers like Balkan Pharmaceuticals now produce it at 100 mg/ml under EU GMP standards, updating the original formulation density.

Why are 10x1ml single-dose ampoules preferred for Trenbolone Hexahydrobenzylcarbonate?

Single-dose 1 ml glass ampoules eliminate the repeated needle penetration of multi-dose vials, which reduces the risk of microbiological contamination over the course of a cycle. Each ampoule in the Balkan Pharmaceuticals Parabolan pack is hermetically sealed and individually sterilised, meaning sterility is maintained independently for every injection event across the 10-ampoule presentation.

How should Balkan Pharmaceuticals Parabolan ampoules be stored correctly?

Parabolan ampoules should be stored at 15–25 °C, protected from direct light and moisture. Glass ampoules are sensitive to thermal shock, so freezing must be avoided. Once an ampoule is opened it must be used immediately, as the single-dose format does not include a preservative system to maintain sterility after the seal is broken. Store in original packaging until the point of use. (2) angle_used

Manufacturer

Balkan Pharmaceuticals' approach to raw material selection for its injectable portfolio is grounded in documented API provenance. For Parabolan, the active pharmaceutical ingredient — Trenbolone Hexahydrobenzylcarbonate — is sourced exclusively from suppliers operating under GMP-compliant synthesis conditions, with incoming material subjected to identity confirmation and purity characterisation before it enters the Chișinău production environment. This upstream control is deliberate: the hexahydrobenzylcarbonate ester is chemically more complex than shorter-chain trenbolone esters, requiring tighter specification tolerances on residual solvent levels and esterification yield to meet the concentration accuracy demanded at 100 mg/ml. The carrier oil and ancillary excipients used in the final formulation are likewise sourced through qualified supplier agreements, with each incoming lot reviewed against a specification that encompasses identity, water content, and peroxide value — parameters directly relevant to injectable oil stability over shelf life. Finished-batch release at Balkan Pharmaceuticals requires passing both HPLC quantification (confirming Trenbolone Hexahydrobenzylcarbonate at the labelled concentration within validated acceptance limits) and LAL endotoxin testing (verifying compliance with the parenteral endotoxin threshold under EU GMP Annex 1). The traceability chain — from incoming API lot certificate through in-process controls to finished-product release documentation — reflects Balkan Pharmaceuticals' positioning as an Established Brand whose manufacturing credibility is built on process discipline rather than marketing claims alone.